|
Thermo Fisher Scientific, the world leader in serving science, announced a strategic data collaboration with Datavant, the data collaboration platform trusted for healthcare, to make it easier for pharmaceutical and biotechnology companies to connect real-world data with clinical research to help them generate stronger evidence, faster.
Thermo Fisher’s PPD clinical research business and Datavant will enable secure connection and analysis of real-world data (RWD), spanning RWD enrichment of randomized clinical trials, PPD CorEvitas Clinical Registries and PPD Evidera solutions.
Datavant enables privacy-preserving tokenization and linkage of patient-level data across more than 350 real-world data partners and 80,000 US hospitals and clinics. With this technology, Thermo Fisher’s PPD clinical research business can securely connect de-identified research datasets and retrieve consented electronic medical record (EMR) data for bespoke RWD generation. Integrating Datavant’s encrypted token technology within Thermo Fisher’s real-world data infrastructure will provide biopharmaceutical and biotech customers with access to enhanced linked patient data and advanced analytics to design more connected studies, improve recruitment and accelerate evidence generation, ultimately supporting better patient outcomes.
The collaboration builds on Thermo Fisher’s broader investments in digital innovation, including its strategic collaboration with OpenAI, to deliver more value and greater scientific innovation to life sciences customers.
“Data interoperability is critical to the next generation of evidence generation,” said Karen Kaucic, president, patient and advisory services, and chief medical officer, clinical research, Thermo Fisher Scientific. “By enabling privacy-protected data connectivity at scale, this collaboration allows us to deliver a more seamless and efficient research experience for our customers.”
“This collaboration with Thermo Fisher underscores Datavant’s role in enabling secure, privacy-preserving data connectivity at scale,” said Arnaub Chatterjee, GM and president of Life Sciences at Datavant. “By combining Datavant’s trusted data linkage technology with Thermo Fisher’s deep clinical research expertise and infrastructure, we’re helping bring richer, more connected patient data into the research process. Reducing friction across the research lifecycle – from clinical trials through real-world evidence – is key so that our shared life sciences partners can generate insights faster and advance better outcomes for patients.”
The collaboration strengthens Thermo Fisher’s leadership in RWE, registry, and observational study services, while complementing the company’s ongoing investments in digital innovation aimed at transforming how data and AI are applied across clinical research and development.
“By integrating Datavant’s capabilities with Thermo Fisher’s data, digital and AI capabilities, we can help our customers accelerate insights and ultimately improve patient outcomes,” said Krishna Cheriath, vice president, head of digital and AI, biopharma services, Thermo Fisher Scientific. “This collaboration represents another milestone in our continued investment in digital transformation to accelerate innovation for our customers.”
Thermo Fisher Scientific Inc is the world leader in serving science, with annual revenue over $40 billion. Its mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.
|